Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

quarter of 2008, the Company plans to file a supplemental new drug application (sNDA) in the U.S. for use of VELCADE in patients with newly diagnosed multiple myeloma, based on the data from this trial, which was conducted under the special protocol assessment (SPA) process with the Food and Drug Administration (FDA). The Company also expects that these data will be presented at the December 2007 meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.

"An approval in front-line multiple myeloma would double the number of patients eligible to receive the benefit of VELCADE," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "We are confident that VELCADE based therapies will become standard of care, since physicians typically use the most active agents in the front-line setting to improve long-term outcomes for patients."

The Phase III VISTA trial is being conducted by the Company and its co-development partner Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (JJPRD). The trial randomized 682 patients with newly diagnosed multiple myeloma, ineligible for stem cell transplantation, to receive either VMP or MP, a recognized standard of care in this treatment setting. Patients were enrolled at 151 clinical trial sites in 22 countries. The primary endpoint of the trial is time-to-disease progression with secondary endpoints, including overall survival, progression-free survival, complete remission rate and safety. Side effects of the VELCADE based therapy were manageable and included those seen in previous VELCADE clinical trials. Professor Jesus San Miguel, M.D., Hematology Department Head, University Hospital of Salamanca, Spain, is the principal investigator.

Conference Call Announcement

In conjunction with this news release, Millennium will host a webcast today, Tuesday, September 18, 2007 at 8:00 A.M. ET. This webcast can be accessed by visiting the Investors section of the Company's website, '/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Balloon Market Investment Report, 2014-2016" report to their ... medical device in percutaneous coronary intervention (PCI), serves not ... as a device for pre-/post-stent dilatations. Therefore, the development ... of PCI. As national economy develops and ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... companies. Competition for innovation, increasing clinical development costs, ... with the fast-changing environment are important factors driving ... and clinical trial costs continue to rise due ... Studies conducted by industry think tanks suggest ...
(Date:9/18/2014)... 2014  KIYATEC announced today that it has ... Research (SBIR) Phase II Contract from the National ... and centers that comprise the National Institutes of ... year award, KIYATEC will expand its 3D breast ... forefront of cancer therapy strategies: 1) cancer,s interaction ...
Breaking Medicine Technology:China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3
... (NASDAQ: OPTR ) today announced the presentation ... (DDW) conference highlighting additional analyses of data from Phase ... the treatment of Clostridium difficile infection (CDI). ... first analysis aimed to identify risk factors associated with ...
... MINNEAPOLIS, May 9, 2011 BioDrain Medical, Inc. (OTC ... FDA-cleared Streamway™ System for automated surgical fluid disposal, announced ... ("EKN"), a New York-based registered broker/dealer, as its exclusive ... terms of the agreement, EKN will assist the Company ...
Cached Medicine Technology:Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 2Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 3Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 4BioDrain Medical, Inc. Retains EKN Financial Services as Its Exclusive Financial Advisor and Placement Agent 2BioDrain Medical, Inc. Retains EKN Financial Services as Its Exclusive Financial Advisor and Placement Agent 3
(Date:9/18/2014)... Savannah, GA (PRWEB) September 18, 2014 ... awarded the Alex Ormond, Jr. Leadership Award by the ... toward improving healthcare and wellness throughout the nation and ... to receive this award,” said Ben. “The Savannah Science ... for 65 years and multiple generations have gone through ...
(Date:9/18/2014)... will convene a one-day conference at the Milken Institute ... on September 25, 2014 to discuss the Global Health ... The purpose of this event is to invite discussion ... five years, including action plans to curtail the current ... the GHSA, international organizations and more than 50 countries ...
(Date:9/18/2014)... the Ebola virus invoke scary scenarios of deadly epidemics, ... are still providing researchers with new insights on how ... published online Sept. 18, 2014, in the journal ... Medical School Singapore detail how the Yersinia pestis bacteria ... the lymph nodes and eventually ride into the lungs ...
(Date:9/18/2014)... 18, 2014 As testosterone treatment ... U.S. courts, Bernstein Liebhard LLP notes that a ... Food & Drug Administration (FDA) subject prescription low ... could greatly reduce their use. The joint meeting ... Advisory Committee, and the Drug Safety and Risk ...
(Date:9/18/2014)... Once again, Hickman’s Family Farms will partner with ... to celebrate PJs & Eggs. The sixth annual event ... 10, 2014. The “breakfast for dinner” will begin at ... Association (AzCA) foster care programs statewide. , Customers ... on October 10 are invited to wear their pajamas ...
Breaking Medicine News(10 mins):Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2Health News:New insights on an ancient plague could improve treatments for infections 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 3Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 4Health News:October 10th Is 6th Annual PJs & Eggs: Hickman’s Family Farms and Breakfast Restaurants Partner to Benefit Arizona Foster Children 2
... Mann HealthDay Reporter , THURSDAY, Feb. 16 (HealthDay ... be a hidden source of arsenic, new research suggests. ... brown rice syrup, is found in some infant formulas. Their ... Health Perspectives . Arsenic is a natural element that ...
... delivery directly into muscle using an autoinjector is faster ... according to a study sponsored by the National Institutes ... School of Medicine researcher. The trial compared the ... how they are administered to patients suffering prolonged seizures ...
... , THURSDAY, Feb. 16 (HealthDay News) -- Doing ... that all Americans must have health insurance would not ... insurance exchanges, but would significantly reduce the number of ... findings from the RAND Corporation, a nonprofit research organization, ...
... Mann HealthDay Reporter , WEDNESDAY, Feb. 15 ... help problem drinkers cut their alcohol consumption, a small ... curbs drinking is not fully understood, but its use ... sadness and nausea, thereby blunting the pleasurable effects of ...
... Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- Researchers report ... kicking off puberty in humans, a finding that offers insight ... who suffer from a rare disease that prevents the start ... family whose members have suffered from the disease confirmed that ...
... Feb. 15 (HealthDay News) -- How fast you walk or how ... odds for dementia or stroke later in life, a new study ... performed in a doctor,s office, noted study author Dr. Erica C. ... tested the walking speed, hand grip strength and cognitive function of ...
Cached Medicine News:Health News:Arsenic Might Be Found in Some Organic Foods: Study 2Health News:Arsenic Might Be Found in Some Organic Foods: Study 3Health News:Wayne State research reveals improved method for paramedics to stop prolonged seizures 2Health News:Wayne State research reveals improved method for paramedics to stop prolonged seizures 3Health News:Wayne State research reveals improved method for paramedics to stop prolonged seizures 4Health News:Health Insurance 'Mandate' Deemed Best Value for Money 2Health News:Stop-Smoking Drug May Also Curb Problem Drinking 2Health News:Gene Linked to Start of Puberty 2Health News:Can Walking Speed, Hand Grip in Middle Age Predict Dementia Risk? 2
Polygraf ID Adapter Cable for LATITUDE® Air-Charged Catheter...
Solid State Manometry Catheter Accessory., ,Manometric calibrators are required for calibration of solid state catheters., ,Each type of catheter requires a unique calibrator....
Sphincter of Oddi Solid State Catheter Adapter Cable for Polygraf ID...
... The ITREL 3 is a battery ... in the U.S., ,Enterra™ Therapy is ... and vomiting associated with gastroparesis when conventional ... of symptons for diabetic or idiopathic patients., ...
Medicine Products: